CervoMed Inc. Insider Trading

CRVO

⊜ Compare

Last 12 months

Insiders bought $3.74M on the open market and sold nothing.

Net open-market

+$3.74M

11 buys · 0 sales

Under a 10b5-1 plan

—

no sales

Insiders who bought / sold

5 / 0

executives and directors

Last open-market buy

Jun 2026

Jun 11, 2026

Get an email when CRVO's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Jun 11	Joshua S Boger Director	Bought	955,414	$3.14	$3M	90%	Form 4
Nov 17, 2025 – Nov 18, 2025	Matthew Winton Chief Commercial and Business	Bought 2 parts	5,000	$8.29 average	41K	50%	Form 4
Nov 17, 2025 – Nov 18, 2025	William Robert Elder CFO, GC & Secretary	Bought 2 parts	3,500	$8.36 average	29K	39%	Form 4
Nov 17, 2025	Sylvie Gregoire Director	Bought 2 parts	21,600	$8.46 average	183K	1.5%	Form 4
Nov 17, 2025	John J Alam CEO & President	Bought 2 parts	21,600	$8.46 average	183K	1.5%	Form 4
Nov 13, 2025 – Nov 14, 2025	Sylvie Gregoire Director	Bought 3 parts	7,847	$7.53 average	59K	0.5%	Form 4
Nov 13, 2025 – Nov 14, 2025	John J Alam CEO & President	Bought 3 parts	7,847	$7.53 average	59K	0.5%	Form 4
Nov 14, 2025	Matthew Winton Chief Commercial and Business	Bought	10,000	$7.57	76K	New	Form 4
Nov 12, 2025	Sylvie Gregoire Director	Bought	5,553	$7.35	41K	0.4%	Form 4
Nov 12, 2025	William Robert Elder CFO, GC & Secretary	Bought	3,500	$7.44	26K	64%	Form 4
Nov 12, 2025	John J Alam CEO & President	Bought	5,553	$7.35	41K	0.4%	Form 4
May 14, 2025	William Robert Elder CFO, GC & Secretary	Bought	4,233	$8.46	36K	334%	Form 4

Jun 11
Joshua S Boger
Director · bought 955,414 at $3.14
$3M
90% of stake
Nov 17, 2025 – Nov 18, 2025
Matthew Winton
Chief Commercial and Business · bought 5,000 at avg $8.29
41K
50% of stake
Nov 17, 2025 – Nov 18, 2025
William Robert Elder
CFO, GC & Secretary · bought 3,500 at avg $8.36
29K
39% of stake
Nov 17, 2025
Sylvie Gregoire
Director · bought 21,600 at avg $8.46
183K
1.5% of stake
Nov 17, 2025
John J Alam
CEO & President · bought 21,600 at avg $8.46
183K
1.5% of stake
Nov 13, 2025 – Nov 14, 2025
Sylvie Gregoire
Director · bought 7,847 at avg $7.53
59K
0.5% of stake
Nov 13, 2025 – Nov 14, 2025
John J Alam
CEO & President · bought 7,847 at avg $7.53
59K
0.5% of stake
Nov 14, 2025
Matthew Winton
Chief Commercial and Business · bought 10,000 at $7.57
76K
New position
Nov 12, 2025
Sylvie Gregoire
Director · bought 5,553 at $7.35
41K
0.4% of stake
Nov 12, 2025
William Robert Elder
CFO, GC & Secretary · bought 3,500 at $7.44
26K
64% of stake
Nov 12, 2025
John J Alam
CEO & President · bought 5,553 at $7.35
41K
0.4% of stake
May 14, 2025
William Robert Elder
CFO, GC & Secretary · bought 4,233 at $8.46
36K
334% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch CRVO, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with CRVO

CompareIntrinsic value

PVCTProvectus Biopharmaceuticals, Inc.

$0.05-2.00%16

ALLRAllarity Therapeutics Inc.

$1.09-3.54%0

ABVCABVC BioPharma Inc.

$1.00+1.52%0

LIPOLipella Pharmaceuticals Inc.

$0.00+0.00%25

CYDYCytoDyn Inc.

$0.23-0.65%0

CANFCan-Fite BioPharma Ltd.

$1.67+3.02%20

MNOVMediciNova Inc.

$1.45+2.11%40

RGBPRegen Biopharma Inc.

$0.00-33.33%25

Spot a number that looks wrong? Check it in CRVO's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing CRVO

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.